



Viyash Scientific Limited

(Formerly known as Sequent Scientific Limited)
Registered Office:
3rd Floor, Srivalli's Corporate, Plot No.290, Road
No.6, Sy.No.33, 34P to 39, Guttala Begumpet,
Jubilee Hills, Hyderabad, Shaikpet, Telangana,
India-500033
T: +91 40 23635000
E: investorrelations@viyash.com
Website: www.viyash.com
CIN: L99999TS1985PLC196357

June 8, 2026

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001

National Stock Exchange of India Limited
Exchange Plaza,
Bandra-Kurla Complex,
Bandra (East),
Mumbai - 400 051

Scrip code: 512529

Scrip code: VIYASH

Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)

Dear Sir/ Madam,

Pursuant to Regulation 30 read with Schedule III of the SEBI Listing Regulations, we hereby inform you that, Alivira Animal Health Limited, Ireland, step-down wholly owned subsidiary of the Company, has entered into a binding agreement today i.e. June 8, 2026, for the acquisition of 100% shareholding of BioForLife Italia s.r.l., Milan, Italy.

The aggregate consideration for the transaction is EUR 16.975 million, structured as follows:

- a. EUR 15.0 million payable at closing; and
- b. EUR 1.975 million as deferred consideration, in accordance with the terms of the transaction documents.

The transaction is subject to fulfilment of the applicable conditions precedent and receipt of such statutory and regulatory approvals as are applicable to the transaction. The details required under Regulation 30 of the SEBI Listing Regulations read with the applicable SEBI circulars are enclosed as **Annexure I**.

We request you to take the same on record.

Yours faithfully,

For Viyash Scientific Limited
(Formerly known as Sequent Scientific Limited)

Yoshita Vora
Company Secretary & Compliance Officer
Encl: A/a



Viyash Scientific Limited

(Formerly known as Sequent Scientific Limited)
Registered Office:
3rd Floor, Srivalli's Corporate, Plot No.290, Road No.6, Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills, Hyderabad, Shaikpet, Telangana, India-500033
T: +91 40 23635000
E: investorrelations@viyash.com
Website: www.viyash.com
CIN: L99999TS1985PLC196357

Annexure I

Sr. No.	Particulars	Details
a.	Name of the target entity, details in brief such as size, turnover etc.	BioForLife Italia s.r.l, Milan, Italy. The target is engaged in marketing and distribution of products of animal health/veterinary products for companion animals. Reported annual sales for CY 2025 were approximately EUR 9.0 million.
b.	Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of the interest and details thereof and whether the same is done at 'arm's length'	No. The acquisition does not fall within related party transactions and the promoter / promoter group / group companies do not have any interest in the target entity.
c.	Industry to which the entity being acquired belongs	Pharmaceuticals- Animal Health / Veterinary Products- Companion Animal
d.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The acquisition is intended to strengthen and scale the Company's presence in Italy in the companion animal segment through an established front-end platform, customer reach and product capabilities.
e.	Brief details of governmental or any regulatory approvals required for the acquisition	Notification under Italian Golden Power Laws (Decree-Law No. 21/2012)
f.	Indicative time period for completion of the acquisition	Initial closing is expected within 3 months from execution of the binding agreement, subject to fulfilment of conditions precedent. Deferred consideration, if payable, is expected to be settled in accordance with the transaction documents within 12 months from closing or earlier upon occurrence of the relevant trigger.
g.	Nature of Consideration whether Cash consideration or share swap and details of the same	Cash consideration



Viyash Scientific Limited

(Formerly known as Sequent Scientific Limited)

Registered Office:

3rd Floor, Srivalli's Corporate, Plot No.290, Road No.6, Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills, Hyderabad, Shaikpet, Telangana, India-500033

T: +91 40 23635000

E: investorrelations@viyash.com

Website: www.viyash.com

CIN: L99999TS1985PLC196357

h.	Cost of acquisition and/or the price at which the shares are acquired	Aggregate consideration of EUR 16.975 million, comprising EUR 15.0 million payable at closing and EUR 1.975 million as deferred consideration, subject to the terms of the transaction documents and customary adjustments as applicable.
i.	Percentage of shareholding / control acquired and / or number of shares acquired	100%
j.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>BioForLife Italia s.r.l is a Company based in Milan, Italy and engaged in marketing and distribution of products for Veterinary use, almost entirely in Italy. The products include medicines, nutraceuticals and testing kits.</p> <p>Date of Incorporation: 24 March, 2010</p> <p>Annual sales (last 3 calendar years): CY 2023: 7.1 Mn € CY 2024: 8.3 Mn € CY 2025: 9.0 Mn €</p>